December 31, 2019 7:13pm

One small wish, after an initial pre-open downslide the oversold were recognized

Cell and gene therapy investors need to be open to better intelligence for portfolio return(s) from RMi


 

 

The Dow closed up +76.30 points (+0.27%), the S&P closed up +9.49 points (+0.29%) and the NASDAQ closed up +26.51 points (+0.30%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday the IBB closed up +0.54% while and XBI closed up +0.54%
  • Monday the IBB closed down -1.38% while and XBI closed down -1.49%
  • Friday the IBB closed down -1.02% while and XBI closed down -1.37%

 

The advance/decline line scenario of 45 covered companies:

  • Tuesday the close was positive with an A/D line of 24/11, 3 flats, 2 reversed merged (HSGX & ONVO), 2 dropped (BTX and CUR) and 3 acquired (ONCE, AST & OSIR);
  • Monday the close was negative with an A/D line of 9/28, 1 flat, 2 reversed merged (HSGX & ONVO), 2 dropped (BTX and CUR) and 3 acquired (ONCE, AST & OSIR);
  • Friday the close was negative with an A/D line of 10/26, 0 flat, 2 reversed merged (HSGX & ONVO), 2 dropped (BTX and CUR) and 3 acquired (ONCE, AST & OSIR);

 

Henry’omics:

On the last trading day of 2019, the cell and gene therapy sectors oversold were recognized – by the algorithms and the “machines”!

In 2019, e climbed a wall of worry, from endpoint meeting and non-meetings, a quarterly earnings downdrafts, over shadowed by trade concerns, potential impeachment, liquidity and volume shortfalls, and lofty valuations that were sold into by trading; just to name a few as the list goes on …!

Indexes rose slightly on Tuesday as markets wrapped up a banner year overcoming concerns about the economy and a trade fight with China.

Tuesday’s performance capped off a strong year for stocks.

  • The S&P 500 was up 28.9% for 2019, its biggest one-year gain since 2013, when it rallied 29.6%.
  • The NASDAQ also had its best one-year performance in six years after rallying 35.2% in 2019.
  • The Dow rose 22.3% in 2019, its best annual performance since 2017.

 

The real question is: whether investors have learned any lessons from risk factors?

 

Decliners:

  • CRISPR Therapeutics (CRSP -$0.94 after Monday’s -$4.17);
  • AxoGen (AXGN -$0.29);
  • Cellectis SA (CLLS -$0.15);
  • Intellia Therapeutics (NTLA -$0.11);
  • Homology Medicine (FIXX n-$0.09);

Incliners:

  • ReNeuron (RENE.L +$9.50 after Monday’s +$2.50 ,Friday’s +$4.00, Thursday’s -$1.00 and last Tuesday’s -$1.00);
  • Sage Therapeutics (SAGE +$0.60 after Monday’s-$1.76);
  • Voyager therapeutics (VYGR +$0.54);
  • Alnylam Pharmaceuticals (ALNY +$0.48 after Monday’s -$2.85);
  • Regenxbio (RGNX +$0.36);

 

The percentage (%) indicators:

  • Tuesday’s range of the 24 upside was +0.05% (RARE) to +16.22% (BLCM) while the 11 downside ranged from -0.05% (BMRN) to -4.96% (VSTM); 
  • Monday’s range of the 9 upside was +0.09% (ADVM) to +10.31% (CLBS) while the 28 downside ranged from -0.03% (GBT) to -9.02% (BLCM); 
  • Friday’s range of the 10 upside was +0.06% (BOLD) to +7.31% (KOOL) while the 20 downside ranged from -0.20% (ALNY) to -8.27% (ADVM); 

 

Upside volume stats:  to compare

  • Tuesday: 6 out of the 24 upside had higher than the 3 month average volume;
  • Monday: 2 out of the 9 upside had higher than the 3 month average volume;
  • Friday: 6 out of the 16 upside had higher than the 3 month average volume;

Downside volume stats:

  • Tuesday: 7 out of the 11 downside had higher than the 3 month average volume;
  • Monday: 10 out of the 28 downside had higher than the 3 month average volume;
  • Friday: 7 out of the 20 downside had higher than the 3 month average volume;

 

3 flat – AGTC, BSTG and CLLS

 

December’s sessions:

Tuesday closed POSITIVE with 11 decliners, 24 advancers, 3 flats, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Monday closed NEGATIVE with 28 decliners, 9 advancers, 1 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Friday closed NEGATIVE with 20 decliners, 10 advancers, 2 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Thursday closed NEGATIVE with 20 decliners, 16 advancers, 2 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Wednesday markets were closed;

Tuesday closed POSITIVE with 10 decliners, 27 advancers, 1 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Monday closed POSITIVE with 2 decliners, 35 advancers, 1 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Friday closed NEGATIVE with 19 decliners, 15 advancers, 3 flats, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Thursday closed POSITIVE with 12 decliners, 24 advancers, 2 flats, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Wednesday closed NEGATIVE with 23 decliners, 13 advancers, 3 flat, 2 dropped (BTX & CUR) and 2 acquired (AST & OSIR) and 2 reversed (HSGX & ONVO);

Tuesday closed NEGATIVE with 22 decliners, 16 advancers, 1 flat, 2 dropped (BTX & CUR) and 2 acquired (AST & OSIR) and 2 reversed (HSGX & ONVO);

Monday closed POSITIVE with 13 decliners, 25 advancers, 1 flat, 2 dropped (BTX & CUR) and 2 acquired (AST & OSIR) and 2 reversed (HSGX & ONVO);

Friday closed NEGATIVE with 24 decliners, 16 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed POSITIVE with 14 decliners, 27 advancers, 0 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 13 decliners, 27 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 17 decliners, 22 advancers, 2 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 9 decliners, 29 advancers, 3 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed POSITIVE with 13 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 12 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 26 decliners, 19 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.